Assenagon Asset Management S.A. decreased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 76.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 476,782 shares of the biopharmaceutical company's stock after selling 1,561,114 shares during the period. Assenagon Asset Management S.A. owned approximately 0.16% of Amicus Therapeutics worth $4,491,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently made changes to their positions in FOLD. OLD Second National Bank of Aurora bought a new stake in Amicus Therapeutics during the third quarter worth approximately $26,000. Hazlett Burt & Watson Inc. lifted its position in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 1,569 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI bought a new stake in shares of Amicus Therapeutics during the 3rd quarter worth $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Amicus Therapeutics in the 3rd quarter worth $55,000.
Amicus Therapeutics Stock Up 1.1 %
Amicus Therapeutics stock traded up $0.10 during trading hours on Tuesday, hitting $9.51. The company had a trading volume of 1,774,523 shares, compared to its average volume of 2,434,944. The firm's fifty day moving average is $9.66 and its 200-day moving average is $10.52. The firm has a market capitalization of $2.84 billion, a P/E ratio of -27.97, a price-to-earnings-growth ratio of 1.43 and a beta of 0.62. Amicus Therapeutics, Inc. has a fifty-two week low of $8.78 and a fifty-two week high of $14.03. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42.
Analyst Ratings Changes
Several brokerages have recently commented on FOLD. Bank of America upped their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, October 17th. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Guggenheim upped their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.88.
Get Our Latest Analysis on Amicus Therapeutics
Insider Transactions at Amicus Therapeutics
In related news, CEO Bradley L. Campbell sold 7,500 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company's stock, valued at approximately $8,884,273.08. The trade was a 0.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 22,901 shares of company stock valued at $259,863. 2.20% of the stock is owned by insiders.
Amicus Therapeutics Profile
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Further Reading
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
